Last reviewed · How we verify
CBD powder form capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CBD powder form capsule (CBD powder form capsule) — Hadassah Medical Organization. CBD interacts with the endocannabinoid system, primarily affecting CB1 and CB2 receptors, though its exact mechanism remains complex and not fully elucidated.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CBD powder form capsule TARGET | CBD powder form capsule | Hadassah Medical Organization | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CBD powder form capsule CI watch — RSS
- CBD powder form capsule CI watch — Atom
- CBD powder form capsule CI watch — JSON
- CBD powder form capsule alone — RSS
Cite this brief
Drug Landscape (2026). CBD powder form capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/cbd-powder-form-capsule. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing